Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

WSW, NY, October 26th, 2026, FinanceWireTumors shrank in 22 of 27 patients treated with NXP200 alone. The results give ...

A new review by a team of researchers from Indonesia, Japan and China, led by Professor Nurhasni Hasan from the Faculty of Pharmacy at Hasanuddin University in Indonesia, examines how emerging local ...

A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines' oral tablet daraxonrasib, branded as Rasonque, reduced ...

Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors.Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) ...

What Is Ibrance, and Why Does It Matter? Ibrance (palbociclib) is a targeted cancer pill for treating certain forms of breast cancer. The FDA has now approved its use combined with other targeted anti ...

The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some ...

People with advanced breast cancer that has spread despite hormone therapy, and with tumors that carry a gene change called an ESR1 mutation, have a new treatment option. Inluriyo blocks estrogen’s ...

SEATTLE — Pancreatic cancer is considered one of the deadliest cancers, with a five-year survival rate of just 13 percent, by some estimates. But a promising new treatment in pill form is transforming ...

Antiresorptive drugs, which reduce bone breakdown, are an important part of treatment for breast cancer that has spread to ...

Scientists have uncovered a critical epigenetic mechanism behind oral cancer, showing that a gene called HOXA5 is switched ...

Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist. Thanks to the Inflation ...